Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 14/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.77 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765149 | 1.00 | PDE3B (0.77) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| SCHEMBL4786350 | 1.00 | PDE3B (0.77) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL83243 | 0.87 | PDE3B (1.00) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Simendan SCHEMBL80460 | 0.87 | PDE3B (1.00) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL1818300 | 0.87 | PDE3B (1.00) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL7417215 | 0.87 | PDE3B (1.00) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL30307096 | 0.86 | PDE3B (0.98) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL27742947 | 0.86 | PDE3B (0.98) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Levosimendan SCHEMBL4737565 | 0.83 | PDE3B (0.91) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 | |
| Simendan SCHEMBL23630217 | 0.81 | PDE3B (0.88) | PDE3BPDE3ATNNC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111514147-B | Levosimendan sodium medicinal composition for acute decompensated heart failure symptoms and preparation method thereof | 成都欣捷高新技术开发股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-111514147-A | Levosimendan sodium medicinal composition for acute decompensated heart failure symptoms and preparation method thereof | 成都欣捷高新技术开发股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2008082871-A1 | FORMULATIONS OF LEVOSIMENDAN FOR PARENTERAL ADMINISTRATION | ORION CORPORATION (FI) | 2008-07-10 | — | — | WO | disclosed |
| EP-1210085-B1 | PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN | ORION CORP (FI) | 2006-01-18 | — | — | EP | disclosed |
| US-6943164-B2 | Pharmaceutical solutions of levosimendan | ORION CORPORATION (FI) | 2005-09-13 | — | — | US | disclosed |
| US-20040106617-A1 | Pharmaceutical solutions of levosimendan | ORION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6730673-B1 | (-)-((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL) PHENYL)HYDRAZONO)PROPANEDINITRILE, IS USEFUL IN THE TREATMENT OF CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2004-05-04 | — | — | US | disclosed |
| EP-1210085-A2 | PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001019334-A2 | PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106617-A1 | Pharmaceutical solutions of levosimendan | TNNI3, TNNC1, F5 | PDE3B 10/4885PDE3A 22/4885TNNC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.